FDA Announces Priority Review For Merrimack's Pancreatic Cancer Drug By: TalkMarkets June 25, 2015 at 10:49 AM EDT Shares of Merrimack are up 7% after announcing FDA priority review for MM-398, a pancreatic cancer drug. Read More >> Related Stocks: Baxter International